IMA is loading

Main Financial Data 2012

Main Data: 31/12 Year 2012
Consolidated income statement (international practice in accordance with IAS/IFRS) Millions/Euro
– total revenues 734.31
– gross industrial income 304.38
– total operating cost 223.77
– operating profit 80.61
– net financial expenses 9.71
– group profit 47.70

 

Consolidated balance sheet Millions/Euro
– working capital 59.36
– non-current assets 240.26
– provision for severance indemnities and other provisions -9.69
– net debt -131.47
– equity pertaining to the group and minority interests 158.46

 

Other information Millions/Euro
– depreciation, amortization and impairment 24.19
– R & D costs 33.69

 

  Euro
Dividend per share 1.00

 

  No.
Employees 3,545

 

  Euro
Share capital 19,150,560

 

Main Data: 30/06 Year 2012
Consolidated income statement (international practice in accordance with IAS/IFRS) Millions/Euro
– total revenues 335.5
– gross industrial income 135.8
– total operating cost 109.4
– operating profit 26.4
– net financial expenses 4.8
– group profit (loss) 12.2

 

Consolidated balance sheet Millions/Euro
– working capital 113.9
– non-current assets 240.6
– provision for severance indemnities and other provisions – 20.1
– net debt – 209.6
– equity pertaining to the group and minority interests 124.8

 

Other information Millions/Euro
– depreciation, amortization and impairment 9.6
– R & D costs 16.6

 

  No.
Employees 3,524

 

  Euro
Share capital 19,150,560

 

Net Sales by Sector: Year 2012
  Millions/Euro  
tea, food & other 280.14 38.2%
pharmaceutical 454.17 61.8%
Total 734.31 100.0%

 

Net Sales by Country: Year 2012
  Millions/Euro  
E.U. (excluding Italy) 246.84 33.6%
Other European countries 76.35 10.4%
North America 95.99 13.1%
Asia & Middle East 166.31 22.6%
Other countries 95.88 13.1%
Total exports 681.37 92.8%
Italy 52.94 7.2%
Total 734.31 100.0%
Dismissclose

IMA Pharma
@ Achema

Explore the dedicated website and get a free entry pass with IMA